A Phase 3 interventional study of Rosuvastatin and Atorvastatin in Acute Coronary Syndrome, sponsored by AstraZeneca. Completed at 102 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-12-17.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.
1,461 studies on the registry are indexed under Acute Coronary Syndrome; 267 are open to participants now.
This study's planned enrollment of 1,160 is above the median of 200 across 869 interventional studies indexed under Acute Coronary Syndrome.
Browse Acute Coronary Syndrome studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Percentage changes in ApoB/ApoA-I levels
Time frame: from Day 0 to 3 months
Percentage changes in LDL-C
Time frame: from Day 0 to 1 month and 3 months
Percentage changes in the hs-CRP and AUC of hs-CRP levels
Time frame: from Day -6 to Day 0
Percentage changes in ApoA-I
Time frame: from Day 0 to 1 month
Showing the first 100 of 102 sites across 11 countries.
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca